Phase 3 N=49 Second Open Label Extension to Bridging Study CTBM100C2303
Pulmonary Infections · Pseudomonas Aeruginosa
Primary: Number of Participants With Adverse Events (AEs) — 23 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=397 Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 10.1; 8.9; 9.1; 9.0 months — p=>0.991
N/A N=216 A Study to Describe Pain Intensity, Pain Relief and Safety of Neosaldina in the Treatment of Tension-type Headaches (TTH) in Healthy Participants
Healthy Volunteers · Tension-type Headache
Primary: Cohort 2: Time-weighted Sum of Pain Intensity Difference From Baseline (0 Hour) to 2 Hours (SPID 0-2) Post-dose — -210 units on a scale
Phase 2 N=30 An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly
Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…
N/A N=36 Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA
Atrial Fibrillation
Primary: Number of Esophageal Lesions. — 1 esophageal lesions
Phase 2 N=35 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
Phase 2 N=63 A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension
Hypertension
Primary: Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in…
Phase 2 N=10 Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Change From Baseline In Serum LDH Levels At Day 28 — 1416; 444.3; -971.7 international units per liter (IU/L)
N/A N=18 Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy
Achilles Tendinopathy
Primary: Change in Cross-sectional Area at the Place of Maximum Tendon Width — 0.8; 0.76; 0.78; 0.69 cm^2 — p=0.722
N/A N=15 Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence
Urinary Incontinence
Primary: Urine Volume Quantification and Impedance Measurements — 46 ml
Phase 2 N=187 A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Ankylosing Spondylitis (AS)
Primary: Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 — 25.5; 51.6 percentage of participants — p=<0.001
N/A N=44 Constraint-induced Movement Therapy (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy
Cerebral Palsy · Hemiplegia · Children
Primary: Change in Score on Assisting Hand Assessment (AHA) — 0.42; 0.56 score — p=<0.01
Phase 2 N=97 A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Select Advanced Malignancies · Kidney Cancer · Clear Cell Renal Cell Carcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose-escalation Phase — 4; 5; 3; 3…
N/A N=70 Imaging Study of Lead Implant for His Bundle Pacing
Cardiac Pacemaker, Artificial
Primary: Implant Success — 75.36 % of subjects with successful implant
Phase 3 N=331 Bupivacaine Effectiveness and Safety in SABER® Trial
Postoperative Pain · Abdominal Surgery
Primary: Mean Pain Intensity on Movement — 4.9; 5.0; 2.8; 3.9 score on a scale — p=0.1473